Juan P Frias
Overview
Explore the profile of Juan P Frias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
3386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frias J, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah V
Diabetes Obes Metab
. 2025 Feb;
27(4):2173-2182.
PMID: 39905643
Aims: People with type 2 diabetes (T2D) and glycated haemoglobin (HbA1c) ≥9% may benefit from fixed-ratio combination therapies such as iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL). Use...
2.
DeFronzo R, Auchus R, Bancos I, Blonde L, Busch R, Buse J, et al.
BMJ Open
. 2024 Jul;
14(7):e081121.
PMID: 39013654
Introduction: Even with recent treatment advances, type 2 diabetes (T2D) remains poorly controlled for many patients, despite the best efforts to adhere to therapies and lifestyle modifications. Although estimates vary,...
3.
Sanyal A, Kaplan L, Frias J, Brouwers B, Wu Q, Thomas M, et al.
Nat Med
. 2024 Jun;
30(7):2037-2048.
PMID: 38858523
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2%...
4.
Harrison S, Frias J, Lucas K, Reiss G, Neff G, Bollepalli S, et al.
Clin Gastroenterol Hepatol
. 2024 Mar;
23(1):103-113.
PMID: 38447814
Background & Aims: In phase 2 studies, efruxifermin, an Fc-FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with non-alcoholic steatohepatitis, now called metabolic dysfunction-associated steatohepatitis (MASH), for which there...
5.
Frias J, De Block C, Brown K, Wang H, Thomas M, Zeytinoglu M, et al.
J Clin Endocrinol Metab
. 2024 Jan;
109(7):1745-1753.
PMID: 38252888
Context: In previous SURPASS studies tirzepatide reduced hemoglobin glycated A1c (HbA1c) and body weight and improved markers of insulin sensitivity and β-cell function to a greater extent than comparators. Objective:...
6.
Harrison S, Frias J, Neff G, Abrams G, Lucas K, Sanchez W, et al.
Lancet Gastroenterol Hepatol
. 2023 Oct;
8(12):1080-1093.
PMID: 37802088
Background: Fibroblast growth factor 21 (FGF21) regulates metabolism and protects cells against stress. Efruxifermin is a bivalent Fc-FGF21 analogue that replicates FGF21 agonism of fibroblast growth factor receptor 1c, 2c,...
7.
Rosenstock J, Frias J, Rodbard H, Tofe S, Sears E, Huh R, et al.
JAMA
. 2023 Oct;
330(17):1631-1640.
PMID: 37786396
Importance: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy and safety of adding tirzepatide vs prandial insulin to...
8.
Alkhouri N, Lazas D, Loomba R, Frias J, Feng S, Tseng L, et al.
Aliment Pharmacol Ther
. 2023 Sep;
58(10):1005-1015.
PMID: 37718721
Background: An approved therapy for nonalcoholic steatohepatitis (NASH) and fibrosis remains a major unmet medical need. Aim: To investigate the histological and metabolic benefits of pegozafermin, a glycoPEGylated FGF21 analogue,...
9.
Sohn M, Frias J, Lim S
Diabetes Obes Metab
. 2023 Aug;
25(12):3560-3577.
PMID: 37649320
Aim: An important characteristic of glucose-lowering therapies (GLTs) is their ability to prevent cardiovascular complications. We aimed to investigate the cardiorenal efficacy and general safety of GLTs. Materials And Methods:...
10.
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, et al.
Lancet
. 2023 Jun;
402(10402):613-626.
PMID: 37385275
Background: Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and...